Neumora Therapeutics, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Watertown, MA
SEC filing record 1 source field available
Fiscal year end
31 December
Neumora Therapeutics, Inc. has filed 244 SEC EDGAR filings since 08 Nov 2021

SEC filing history

Showing 176-200 of 244 matching filings.

Per page
25
Current page
8
4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filing date
27 Sep 2023
Reporting date
26 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filing date
27 Sep 2023
Reporting date
26 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D File 005-94162

SC 13D

Filing date
27 Sep 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filing date
25 Sep 2023
Reporting date
22 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filing date
25 Sep 2023
Reporting date
22 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
21 Sep 2023
Reporting date
19 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
20 Sep 2023
Reporting date
19 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
20 Sep 2023
Reporting date
19 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
20 Sep 2023
Reporting date
19 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-274593

S-8

Filing date
20 Sep 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
19 Sep 2023
Reporting date
19 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
19 Sep 2023
Reporting date
19 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
424B4 File 333-274229

424B4

Filing date
18 Sep 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
18 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-274229

EFFECT filing

Filing date
14 Sep 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SEC STAFF LETTER

SEC STAFF LETTER filing

Filing date
14 Sep 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
14 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 SUBMISSION

Filing date
14 Sep 2023
Reporting date
14 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .